Advertisement

Topics

Kite Reports Fourth Quarter and Full Year 2016 Financial Results

08:00 EST 28 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Strong Execution Across Clinical Development, Pipeline, Manufacturing and Pre-Commercial Activities in 2016 On Track to Complete Rolling Biologics License Application to the U.S. Food and Drug Adminis...

Other Sources for this Article

Kite Pharma, Inc.
Christine Cassiano
SVP, Corporate Communications & Investor Relations
ccassiano@kitepharma.com
or
Greg Mann
VP, Investor Relations
gmann@kitepharma.com

NEXT ARTICLE

More From BioPortfolio on "Kite Reports Fourth Quarter and Full Year 2016 Financial Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...